Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
Zhihao Lü(Nanjing Tech University), Lin Shen(Hangzhou Normal University), Li Ren Kong(Nanyang Technological University), Hu Liu(Nanjing Medical University), Wensheng Qiu(Qingdao University), Buhai Wang(Northern Jiangsu People's Hospital), Aziz Zaanan(Université Paris Cité), Shegan Gao(Henan University of Science and Technology), Lei Yang(Harbin Medical University), Liying Xue(Hebei Medical University), Wenbin Yue(Daqing Oilfield General Hospital), Guogui Sun(Tangshan People's Hospital), Yongqian Shu(Jiangsu Province Hospital), Yanqiao Zhang(Harbin Medical University), Marie‐Pierre Galais(Centre François Baclesse), Yan Wang(Stanford University), Haoyu Li(Qingdao University), Na Li(Hunan Cancer Hospital), Zheng Liu(Tongji Hospital), Gaofeng Li, Xiuwen Wang(Second Hospital of Shandong University), Lianke Liu(Jiangsu Province Hospital), Zhuo Ma, Yinghua Ji(First Affiliated Hospital of Xinxiang Medical University), Tongjian Cui(Fujian Medical University), Guochun Cao(Jiangsu Cancer Hospital), Junye Wang(Sun Yat-sen University), Yueyin Pan(University of Science and Technology of China), Xinfang Hou(Zhengzhou University), Hui Luo(Jiangxi Provincial Cancer Hospital)
Cited by 494
Related Papers
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
|Nature|2021|687
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504